In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Monopar Therapeutics Inc (MNPR – Research Report), with a price target of $33.00. The company’s shares closed last Tuesday at $3.82, close to its 52-week low of $3.70.
According to TipRanks.com, Roy is a 5-star analyst with an average return of 21.3% and a 36.3% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Actinium Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Monopar Therapeutics Inc with a $17.67 average price target.
The company has a one-year high of $17.01 and a one-year low of $3.70. Currently, Monopar Therapeutics Inc has an average volume of 75.96K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
Read More on MNPR: